ScreenPoint Medical plans a major expansion in the sales and research efforts behind Transpara, its artificial intelligence (AI) breast cancer screening software.
Transpara has been cleared in the U.S. and Europe and is currently in use in 30 countries worldwide, the company said. In 2022, the company will expand its global team and initiate further research and development, including new features to meet the growing global demand for the software.
Transpara aids in reading mammograms to find cancers faster and at an earlier stage, said the company, which is based in Nijmegen, The Netherlands.
"Given the increasing demand for the product and with the pressure on radiologists and the increasing incidence of breast cancer worldwide, it is vital we make optimal use of this new technology to find cancers faster and earlier," said ScreenPoint chief executive Nico Karssemeijer, PhD, in a news release.
